REG - BiVictriX Therapcts. - Director Dealing

Bivictrix TherapeuticsAnnouncement

23/09/2021 12:55

RNS Number : 7970M
  
BiVictriX Therapeutics PLC
  
23 September 2021
  
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
 
23 September 2021
 
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
 
Director Dealing 
 
Alderley Park, 23 September 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces the following dealing in the  Company's ordinary shares of 1 pence each ("Ordinary Shares"). 
 
On 22 September 2021, Mr Iain Ross, the Company's Non-Executive Chairman, purchased 100,000 Ordinary Shares at a weighted average price of 19.42 pence each. 
 
Following the transaction, Mr Ross is benefically interested in 300,000 Ordinary Shares, representing 0.45% of the Company's total issued share capital.  
 
 
-Ends-
 
 
 



For more information, please contact: 



BiVictriX Therapeutics plc








Tiffany Thorn, Chief Executive Officer
Iain Ross, Chairman 


 
Email: info@bivictrix.com 














SP Angel Corporate Finance LLP (NOMAD and Broker)


Tel: +44 (0) 20 3470 0470


 




David Hignell, Caroline Rowe (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)






 




 
Consilium Strategic Communications








Ashley Tapp, Suki Virji, Priit Piip


Tel: +44 (0) 20 3709 5700
Email: Bivictrix@consilium-comms.com 





















 
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities. 
 
The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting. 
 
BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.
 
Find out more about BiVictriX online at www.bivictrix.com 
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.



1. 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Iain Ross  




2. 


Reason for the Notification




a)


Position/status


Non-Executive Chairman 




b)


Initial notification/Amendment


Initial notification




3. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


BiVictriX Therapeutics plc 




b)


LEI


213800ZI85IZNA6N3L53




4. 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the Financial instrument, type of instrument


Ordinary Shares of 1 pence each
GB00BNXH3K91




Identification code








b)


Nature of the transaction


Purchase of 100,000 Ordinary Shares




c)


Price(s) and volume(s)


 



Price(s)


Volume(s)




1.    19.375 pence
 
2.    19.45 pence 
 
3.    19.45 pence 
 


 43,507
30,848
25,645








d)


Aggregated information:
-  Aggregated volume
-  Price





Price(s)


Volume(s)




 
19.42p (weighted average)
 


 
100,000



 




e)


Date of the transaction


22 September 2021




f)


Place of the transaction


AIM, London Stock Exchange  



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHBBGDCISDDGBX